Investors Buy Shares of Iqvia (IQV) on Weakness

Investors purchased shares of Iqvia Holdings Inc (NYSE:IQV) on weakness during trading hours on Friday. $71.32 million flowed into the stock on the tick-up and $34.42 million flowed out of the stock on the tick-down, for a money net flow of $36.90 million into the stock. Of all stocks tracked, Iqvia had the 32nd highest net in-flow for the day. Iqvia traded down ($1.53) for the day and closed at $126.89

A number of analysts have recently issued reports on IQV shares. ValuEngine downgraded shares of Iqvia from a “buy” rating to a “hold” rating in a report on Friday, June 22nd. Royal Bank of Canada reaffirmed a “buy” rating and set a $129.00 price target on shares of Iqvia in a report on Wednesday, July 25th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $97.00 price target on shares of Iqvia in a report on Wednesday, July 25th. Stifel Nicolaus raised their price target on shares of Iqvia from $128.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, July 25th. Finally, Barclays reaffirmed an “overweight” rating and set a $130.00 price target (up previously from $120.00) on shares of Iqvia in a report on Wednesday, July 25th. Five investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Iqvia has an average rating of “Buy” and a consensus price target of $126.95.

The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.13 and a current ratio of 1.13. The company has a market capitalization of $26.21 billion, a price-to-earnings ratio of 29.75, a P/E/G ratio of 1.86 and a beta of 0.70.

Iqvia (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 24th. The medical research company reported $1.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.15. Iqvia had a net margin of 12.68% and a return on equity of 13.51%. The firm had revenue of $2.57 billion for the quarter, compared to analysts’ expectations of $2.50 billion. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. As a group, equities analysts expect that Iqvia Holdings Inc will post 5.13 earnings per share for the current year.

In other news, insider Robert Parks sold 871 shares of the stock in a transaction that occurred on Thursday, August 2nd. The shares were sold at an average price of $124.34, for a total value of $108,300.14. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Ronald A. Rittenmeyer sold 7,680 shares of the stock in a transaction that occurred on Thursday, July 26th. The stock was sold at an average price of $122.41, for a total transaction of $940,108.80. The disclosure for this sale can be found here. Insiders sold a total of 978,777 shares of company stock worth $121,566,089 in the last quarter. Company insiders own 6.00% of the company’s stock.

Large investors have recently modified their holdings of the company. Strs Ohio raised its stake in Iqvia by 110.4% during the 3rd quarter. Strs Ohio now owns 43,934 shares of the medical research company’s stock worth $5,699,000 after acquiring an additional 23,053 shares during the period. Oakbrook Investments LLC raised its stake in Iqvia by 175.8% during the 3rd quarter. Oakbrook Investments LLC now owns 16,645 shares of the medical research company’s stock worth $2,160,000 after acquiring an additional 10,610 shares during the period. Aperio Group LLC raised its stake in Iqvia by 3.3% during the 3rd quarter. Aperio Group LLC now owns 90,750 shares of the medical research company’s stock worth $11,774,000 after acquiring an additional 2,940 shares during the period. Nisa Investment Advisors LLC raised its stake in Iqvia by 251.1% during the 3rd quarter. Nisa Investment Advisors LLC now owns 38,970 shares of the medical research company’s stock worth $5,056,000 after acquiring an additional 27,870 shares during the period. Finally, Gateway Investment Advisers LLC raised its stake in Iqvia by 9.1% during the 3rd quarter. Gateway Investment Advisers LLC now owns 6,770 shares of the medical research company’s stock worth $878,000 after acquiring an additional 563 shares during the period. Hedge funds and other institutional investors own 90.40% of the company’s stock.

About Iqvia (NYSE:IQV)

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

See Also: Trading Strategy Examples and Plans

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply